Deutsche Bank AG Takes Position in Kura Oncology, Inc. $KURA

Key Points

• Deutsche Bank AG acquired 91,003 shares of Kura Oncology during the second quarter, valued at approximately $998,000 and representing a 0.10% stake. Several other institutional investors also increased or initiated positions.
• Kura Oncology reported a quarterly loss of $0.77 per share, beating estimates of a $0.88 loss, while revenue of $20.87 million exceeded expectations. Despite the earnings improvement, the company continues to report substantial negative margins and return on equity.
• Wall Street maintains a generally positive outlook, with a consensus “Moderate Buy” rating and a $25.40 price target versus the stock’s $12.66 opening price. However, insiders sold a combined 120,761 shares worth about $1.28 million over the past 90 days.

Deutsche Bank AG bought a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 91,003 shares of the company's stock, valued at approximately $998,000. Deutsche Bank AG owned 0.10% of Kura Oncology at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. IFP Advisors Inc raised its holdings in Kura Oncology by 115.3% during the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company's stock worth $25,000 after purchasing an additional 1,284 shares during the last quarter. Allworth Financial LP lifted its position in shares of Kura Oncology by 59.9% during the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company's stock valued at $43,000 after acquiring an additional 1,553 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Kura Oncology by 49.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company's stock worth $60,000 after acquiring an additional 1,888 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Kura Oncology by 471.3% in the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company's stock valued at $70,000 after purchasing an additional 9,958 shares in the last quarter. Finally, Brevan Howard Capital Management LP bought a new stake in Kura Oncology in the second quarter valued at $80,000.

Kura Oncology Price Performance

Shares of NASDAQ:KURA opened at $12.66 on Monday. Kura Oncology, Inc. has a twelve month low of $7.36 and a twelve month high of $13.90. The company has a 50-day moving average price of $10.86 and a two-hundred day moving average price of $9.65. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $1.13 billion, a PE ratio of -3.76 and a beta of 0.38.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The company had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. Equities analysts forecast that Kura Oncology, Inc. will post -3.23 EPS for the current year.

Insider Activity at Kura Oncology

In related news, insider Teresa Brophy Bair sold 31,487 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $12.63, for a total value of $397,680.81. Following the transaction, the insider owned 195,444 shares of the company's stock, valued at $2,468,457.72. This represents a 13.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mollie Leoni sold 84,929 shares of the company's stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the sale, the insider directly owned 182,345 shares of the company's stock, valued at approximately $1,790,627.90. This represents a 31.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 120,761 shares of company stock worth $1,283,346. Corporate insiders own 7.60% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on KURA. Citigroup reissued a "market outperform" rating on shares of Kura Oncology in a research report on Monday, August 24th. Wells Fargo & Company set a $24.00 price target on shares of Kura Oncology in a research report on Thursday, June 4th. Jefferies Financial Group set a $24.00 target price on Kura Oncology in a research report on Thursday, May 28th. Raymond James Financial set a $24.00 price objective on shares of Kura Oncology in a report on Monday, August 24th. Finally, Oppenheimer set a $24.00 price target on shares of Kura Oncology in a research report on Thursday, May 28th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $25.40.

About Kura Oncology

Kura Oncology, Inc NASDAQ: KURA is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.

Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source